Mesoblast Ltd (DE:LWBA)
FRANKFURT:LWBA

Mesoblast Stock Price & Analysis

0 Followers

LWBA Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€2.12 - €5.75
Previous Close€3.5
Volume0.00
Average Volume (3M)1.04K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$85.11M
Total Debt (Recent Filing)$109.63M
Price to Earnings (P/E)-5.9
Beta2.28
Next EarningsFeb 23, 2023
EPS Estimate-€0.19
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.60
Shares Outstanding147,315,663
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume90
30 Day Avg. Volume1,040
Price to Book (P/B)-9.22
Price to Sales (P/S)41.71
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-6.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside-32.04% Downside
Rating ConsensusModerate Sell
AlphaN/A
Number of Analyst Covering1


Financials


LWBA FAQ

What was Mesoblast’s price range in the past 12 months?
Mesoblast lowest stock price was €2.12 and its highest was €5.75 in the past 12 months.
    What is Mesoblast’s market cap?
    Currently, no data Available
    When is Mesoblast’s upcoming earnings report date?
    Mesoblast’s upcoming earnings report date is Feb 23, 2023 which is in 79 days.
      How were Mesoblast’s earnings last quarter?
      Mesoblast released its earnings results on Nov 22, 2022. The company reported -€0.115 earnings per share for the quarter, beating the consensus estimate of -€0.154 by €0.039.
        Is Mesoblast overvalued?
        According to Wall Street analysts Mesoblast’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Mesoblast pay dividends?
          Mesoblast does not currently pay dividends.
          What is Mesoblast’s EPS estimate?
          Mesoblast’s EPS estimate is -€0.19.
            How many shares outstanding does Mesoblast have?
            Mesoblast has 147,424,240 shares outstanding.
              What happened to Mesoblast’s price movement after its last earnings report?
              Mesoblast reported an EPS of -€0.115 in its last earnings report, beating expectations of -€0.154. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Mesoblast?
                Currently, no hedge funds are holding shares in DE:LWBA

                ---

                Mesoblast Stock Smart Score

                2
                Underperform
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -32.90%
                12-Months-Change

                Fundamentals

                Return on Equity
                -15.81%
                Trailing 12-Months
                Asset Growth
                -5.17%
                Trailing 12-Months
                The Mesoblast Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Mesoblast Ltd

                Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                Race Oncology Ltd.
                PYC Therapeutics Limited
                Athersys
                Pluri
                Teva Pharmaceutical

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis